Last reviewed 2026-05-28 · How we verify

Vistabex

Azienda Ospedaliera Universitaria Integrata Verona · Phase 2 active Small molecule ✓ Verified May 2026

Vistabex is a Small molecule drug developed by Azienda Ospedaliera Universitaria Integrata Verona. It is currently in Phase 2 development. Also known as: Botulinum Toxin.

Vistabex is a treatment being studied for Hemifacial Paralysis, in combination with Juvederm. The exact mechanism of Vistabex is not specified in the available information, but it is being evaluated in a clinical trial in conjunction with onabotulinumtoxin A and hyaluronic acid fillers.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Vistabex
Also known as	Botulinum Toxin
Sponsor	Azienda Ospedaliera Universitaria Integrata Verona
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Onabotulinumtoxin A and Hyaluronic Acid Fillers in the Treatment of Facial Paralysis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vistabex CI brief — competitive landscape report
Vistabex updates RSS · CI watch RSS
Azienda Ospedaliera Universitaria Integrata Verona portfolio CI

Frequently asked questions about Vistabex

What is Vistabex?

Vistabex is a Small molecule drug developed by Azienda Ospedaliera Universitaria Integrata Verona.

Who makes Vistabex?

Vistabex is developed by Azienda Ospedaliera Universitaria Integrata Verona (see full Azienda Ospedaliera Universitaria Integrata Verona pipeline at /company/azienda-ospedaliera-universitaria-integrata-verona).

Is Vistabex also known as anything else?

Vistabex is also known as Botulinum Toxin.

What development phase is Vistabex in?

Vistabex is in Phase 2.

Manufacturer: Azienda Ospedaliera Universitaria Integrata Verona — full pipeline
Therapeutic area: All drugs in Other
Also known as: Botulinum Toxin

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing